* Financial year 2019 guidance, updated in July, confirmed:
revenues in range of 65 mln to 72 mln eur
* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS
MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS
WITH MODERATE TO SEVERE ATOPIC DERMATITIS
FRANKFURT, Feb 25 German biotech firm Morphosys
is in talks with potential partners to bring its debut
drug, a therapeutic antibody against leukaemia, to Europe.